Anti-PPP6C/Ppv antibody [EPR8764]

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-PPP6C/Ppv antibody [EPR8764] (AB131335)

Immunofluorescent analysis of HeLa cells labelling PPP6C/Ppv with ab131335 at 1/100 dilution.

• Flow Cyt (Intra)

Unknown

Flow Cytometry (Intracellular) - Anti-PPP6C/Ppv antibody [EPR8764] (AB131335)

Intracellular Flow Cytometry analysis ofHeLa cells labelling PPP6C/Ppv with purified ab131335 at a dilution of 1/280 (red). Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. An Alexa Flour^® 488-conjugated goat anti-rabbit IgG (1/2000) was used as the secondary antibody. Black - Isotype control, rabbit monoclonal IgG. Blue - Unlabelled control, cells without incubation with primary and secondary antibodies.

• WB

Unknown

Western blot - Anti-PPP6C/Ppv antibody [EPR8764] (AB131335)

All lanes:

Western blot - Anti-PPP6C/Ppv antibody [EPR8764] (ab131335) at 1/1000 dilution

Lane 1:

HeLa cell lysate at 10 µg

Lane 2:

Fetal thymus tissue lysate at 10 µg

Lane 3:

293T cell lysate at 10 µg

Lane 4:

Jurkat cell lysate at 10 µg

Secondary

All lanes:

Goat anti-rabbit HRP conjugated at 1/2000 dilution

Predicted band size: 35 kDa

false

• OI-RD Scanning

Unknown

OI-RD Scanning - Anti-PPP6C/Ppv antibody [EPR8764] (AB131335)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

• WB

CiteAb

Western blot - Anti-PPP6C/Ppv antibody [EPR8764] (AB131335)

Western Blotting using Anti-PPP6C/Ppv antibody [EPR8764], ab131335. Publication image from Bai, J. et al., 2015, Nat Commun, 26138368. Legend direct from paper.

Inhibition of ppp6c is functionally important for the biological effects of miR-31 in epidermal hyperplasia.(a,b) Western blotting of ppp6c expression in the epidermis of normal skin derived from four healthy individuals (Ctr-1 to 4) or in psoriatic lesions derived from four patients with psoriasis (Pso-1 to 4). (c) Immunohistochemical staining of ppp6c in skin sections derived from healthy or psoriatic skin. Scale bar, 100 µm. (d) Primary mouse keratinocytes were transfected with scramble siRNA (Ctr) or with ppp6c siRNA (siRNA). Cell lysates were immunoblotted with anti-ppp6c or anti-actin. (e) Cell cycle analysis of mouse primary keratinocytes transfected with scrambled siRNA or ppp6c siRNA. (f) Western blotting of ppp6c expression in epidermis derived from lentiviral shRNA-control (LV-Ctr) or lentiviral shRNA-ppp6c (LV-shRNA) treated mice. (g) H&E staining of the back skin injected with LV-Ctr or LV-shRNA in mice applied with IMQ. Dotted line indicates the border between the epidermis and dermis. Scale bar, 100 µm. (h) Acanthosis of the back skin injected with LV-Ctr or LV-shRNA in mice applied with IMQ. (i) Immunohistochemical staining of Ki67 in skin sections derived from mice injected with LV-Ctr or LV-shRNA prior to IMQ painting. Dotted line indicates the border between the epidermis and dermis. Scale bar, 50 µm. Values (a,d,f) were expressed as fold changes relative to Ctr-1 (a), to scramble siRNA (d), or to lentiviral shRNA-control (f), and normalized to β-actin. *P<0.05, **P<0.01, two-tailed Student's t-test. Data (c–i) are representative of two independent experiments with three to five samples per group.

false